myelodysplastic syndrome
-
BMS Cancer Drug’s New FDA Nod Puts It on Path to Reach Blockbuster Status
Bristol Myers Squibb drug Reblozyl is now approved as a first-line therapy for anemia caused by myelodysplastic syndromes, a group of blood cancers. It’s the third indication for the drug, which analysts project could top $4 billion in peak sales.
-
Roivant Sciences launches Hemavant to chase BMS in anemia from blood disease
An Eisai drug that produced disappointing data in a myelodysplastic syndrome study is getting another shot under a newly launched Roivant Sciences subsidiary, Hemavant. Roivant executives say the small molecule could be a safer, more effective alternative to MDS therapies marketed by Bristol Myers Squibb.
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
BMS, Acceleron blood cancer drug to undergo FDA expert panel review
The companies said the FDA’s Oncologic Drugs Advisory Committee would review their application for Reblozyl in myelodysplastic syndrome. The drug, which won approval for a blood disorder last month, was developed under a partnership between Acceleron and Celgene, which BMS has since acquired.
-
Stanford, Notable Labs and Tempus collaborate on personalized medicine research for blood cancer
The feasibility study was meant to see whether personalized cancer genetic sequencing and drug sensitivity recommendations could be done in a “clinically reasonable amount of time.”
-
Celgene, Acceleron file for approval of blood disease drug luspatercept
Approval of luspatercept in myelodysplastic syndrome and beta-thalassemia is expected in April 2020, or as early as December of this year if it receives FDA priority review, an analyst wrote.